We investigated the possibility that a proportion of children with sporadic rhabdomyosarcoma (RMS) carry constitutional mutations of the p53 tumor suppressor gene. 33 patients with sporadic RMS at two large outpatient pediatric oncology clinics submitted blood samples. Genomic DNA was extracted from peripheral blood leukocytes and PCR was used to amplify exons 2-11 of the p53 gene. Amplified genomic DNA was screened for the presence of germline p53 mutations using single-strand conformation polymorphism (SSCP) analysis. The DNA sequence of those samples that showed aberrant migration of bands on SSCP analysis was determined to identify the precise nature of the gene mutations. Patient records were reviewed to assess clinical correlates of the mutant p53 carrier state. Heterozygous constitutional mutations were detected in 3/33 patient samples screened. Two of these missense mutations are located in exon 7 and one in exon 8 of the p53 gene. The presence of mutations was not correlated with tumor histology, stage, or site. However, an association between young age at diagnosis and presence of a constitutional p53 mutation was noted: 3/13 children under the age of 3 yr at diagnosis carried mutations, whereas none of 20 children over 3 yr of age at diagnosis harbored a detectable constitutional mutation. These results in children with RMS corroborates previous findings in other clinical settings suggesting that the mutant p53 carrier state may predispose individuals to malignancy at an early age. Although this study did not assess whether the mutations were preexisting or new germline alterations, assessment of close relatives of RMS patients for cancer risk and predictive genetic testing may be indicated. (J. Clin. Invest. 1995Invest. . 95:1606Invest. -1611
Introduction
The p53 tumor suppressor gene, located on the short arm of human chromosome 17 (1, 2) , encodes a 53-kd nuclear phos-phoprotein that functions as a negative regulator of cell proliferation (3, 4) . p53 is a transcription activating factor that acts as a "checkpoint" control late in GI to block the progression of cells through the cell cycle, particularly in the presence of DNA damage (5) (6) (7) (8) (9) .
Alterations of the p53 gene or its encoded protein are the most common genetic abnormalities observed in human cancers (10, 11) , having been associated with virtually every sporadically occurring malignancy ( 12, 13 ) . The presence of heterozygous p53 mutations in an individual's constitutional cells confers a high risk for the development of a diverse set of malignancies (14) . Such germline p53 mutations were initially identified in affected members of families with the Li-Fraumeni syndrome (LFS)' ( 15, 16) . This autosomal, dominantly inherited disorder is characterized by the presence of soft tissue and osteosarcomas, early onset breast cancers, adrenocortical carcinomas, brain tumors, and acute leukemias in affected family members (17) (18) (19) (20) . Other features of LFS include the early age at diagnosis of tumors and the propensity of affected individuals to develop multiple primary tumors (14, 19, 20) . The relationship between LFS and constitutional p53 mutations is complex. Although the majority of LFS families analyzed to date harbor germline p53 mutations in the coding region of the gene ( 15, 16, 21, 22) , some LFS families lack detectable mutations (23, 24) , and constitutional mutations have been identified in some cancer patients without a family history of malignancy (25) (26) (27) (28) (29) (30) (31) .
The presence of a childhood sarcoma is the primary criterion for the diagnosis of LFS. In addition, despite potential bias through ascertainment methods, rhabdomyosarcoma (RMS) is the most frequently diagnosed sarcoma in this syndrome. Based on these observations, we elected to study a series of unselected pediatric RMS patients from two large institutions in order to determine the frequency of constitutional p53 mutations in this population and to correlate these findings with any distinct characteristics of these patients or their tumors. We chose to study patients who do not have family histories suggestive of a cancerpredisposing syndrome, so that the frequency of constitutional p53 mutations in patients with apparently sporadic disease could be assessed.
Genomic DNA extracted from peripheral blood lymphocytes of children with RMS was screened using PCR and singlestrand conformation polymorphism (SSCP) analysis. All coding exons of the gene were analyzed. Those cycles. The reaction was initiated with a 10-min incubation at 85°C and terminated with a 7-min incubation at 72°C followed by 3 min at 94°C.
5 MI of the PCR product was added to an equal volume of loading buffer (95% formamide, 20 mM EDTA, 0.05% bromphenol blue, 0.05% xylene cyanol). The samples were denatured at 85°C for 5 min and loaded immediately onto an acrylamide-Tris-buffered EDTA nondenaturing gel. The gels contained 4.5-9.0% acrylamide and 2-10% glycerol, depending on the exon fragment being analyzed. Electrophoresis was performed at 25 W for 6-7 h or at 10 W for 15-17 h at room temperature. The gel was blotted onto 3M filter paper (Fisher, Toronto, ON), dried, and exposed to x-ray film (Eastman Kodak Co., Rochester, NY) with an intensifying screen at -70°C for 4-72 h. Each fragment was analyzed using two or three electrophoretic conditions, again depending on the specific fragment being analyzed. Each gel carried both positive and negative controls to ensure that known mutations could be detected. A fresh aliquot of DNA from each sample determined to be abnormal by detectable band shifts on SSCP analysis was amplified with the SSCP primers encompassing the respective abnormal region. Fragments were directly subcloned into a T-tailed pBSK vector, and at least six independent clonse were sequenced in both directions by the Sanger dideoxide method with a Sequenase 2 ( 13, 22) , suggesting that they are not likely to represent polymorphisms.
Discussion
RMS is thr most common sarcoma of childhood and accounts for 10-15% of all childhood cancers (36) . The etiology of this tumor is unknown, but several lines of evidence suggest that a proportion of patients with RMS are genetically susceptible to the development of the tumor. In 1969, Li and Fraumeni first defined an increased risk of cancers, especially breast cancer, in the relatives of patients with RMS (17, 18) . Subsequent studies of RMS patients and their families have revealed an increased relative risk of early onset breast cancer in mothers of patients with RMS (37) . This association has not been seen consistently in mothers of other childhood cancer patients. RMS is one of the tumors observed as a second cancer in survivors of childhood cancer (38) and is the most common sarcoma described in LFS (19, 20) . A study of RMS tumor samples revealed a high frequency of alterations at the p53 tumor suppressor locus (39, 40) . The current study provides genetic evidence that RMS, in a subset of patients, is associated with the carrier state of a constitutionally altered allele of the p53 tumor suppressor gene. Previous surveys have sought to identify the clinical situations associated with increased risk of harboring a germline p53 mutation. Among families with LFS, the risk of carriage of a constitutional p53 mutation has been variable among studies. Initially, it had been demonstrated that 5/5 families with classic LFS harbored mutations (15) , yet subsequent studies have been able to demonstrate mutations only in 70% of LFS families (14, 22, 23, 25, 41) . Toguchida et al. (26) analyzed the entire coding sequence of the p53 gene in 196 sarcoma patients of all ages, most of whom had osteosarcoma. 15 of these patients were specifically recruited to the study because of an unusual family history of cancer. Eight individuals with germline p53 mutations were found, although only two of these were patients without an unusual family history of cancer. The authors did not note whether a tendency to early onset of disease in the mutant p53 carriers existed. Among women with breast cancer, germline yields an amino acid change from asparagine to serine. A, adenine; G, guanine; C, cytosine; T, thymine; W.T., wild-type sequence; MUT., mutant sequence.
A C 4/59 harbored germline p53 mutations. Adrenocortical carcinoma, an extremely rare tumor of childhood except in the setting of Beckwith-Wiedemann syndrome or LFS, has been associated with the p53 carrier state in 3/6 children studied (42) . None of these individuals had a family history of cancer. In another survey, 2/6 children with adenocortical carcinoma in LFS families harbored germline p53 mutations (43) . A survey of individuals with childhood acute lymphoblastic leukemia revealed 1 carrier of a germline p53 mutation among 25 patients studied (44) . A recent survey of 235 unselected children with osteosarcoma found 7 (2.5%) who harbored mutations (45) . Three of these children have no family history of cancer. In summary, the risk of carriage of a p53 mutation for a cancer patient without a strong family history of malignancy, a second cancer, or adrenocortical carcinoma is very low. We report here that 3/33 children (9.1%) with RMS without a family history of cancer or second cancers harbor constitutional p53 mutations. This represents the highest proportion of patients to be described to date, except those with adrenocortical carcinoma who carry mutations but who have no suggestive family history or second cancers. All mutations were missense and predict amino acid substitutions. Gender, tumor site, histology, and clinical group showed no correlation with the presence or absence of mutations. However, 3/13 children (23%) diagnosed before the age of 3 yr carried p53 mutations, whereas 0/ 20 children 3 yr or older at diagnosis harbored mutations. The association between young age at diagnosis and genetic predisposition has been observed in other settings, such as in retino- (24) . Other candidate genes for RMS predisposition would include the murine double minute gene, mdm-2, which encodes a protein that complexes with P53 and may inhibit its function (49, 50) . In fact, MDM-2 has been shown to be amplified or overexpressed in some sarcoma subtypes (50) (51) (52) . Finally, children with RMS may also develop their disease as a consequence of alterations of other cancer-associated genes such as the neurofibromatosis-1 gene.
The previously observed finding of early onset RMS in LFS families together with the relatively high frequency of germline p53 mutations in early onset RMS observed in this cohort suggests a broader definition of LFS, as well as possible biologic differences between childhood RMS of early and late onset. These observations may in turn lead to novel therapeutic approaches to childhood RMS and could influence the clinical management of RMS survivors and family members.
